Founder’s statement
We’re addressing
a huge unmet
medical need
Closeup of two hands with gloves holding a test container

About us » Our founder

Severe impact on global economies

”CHRONIC PAIN has a severe impact not only on individual sufferers’ physical and mental health  but also on national economies . In the USA, almost 20% of adults suffer from  chronic pain (2016) with an estimated annual cost of $560 billion in direct medical costs, lost productivity, and disability programs.

Existing chronic pain drugs are only partly effective, and only for some patients, and they are associated with significant side effects. PharmNovo’s mission is to develop safe and effective medicines for chronic pain treatment.

Our team has taken our lead candidate PN6047 successfully through preclinical studies and it is now engaged in first in man clinical studies. This is a great achievement for a small Biopharma company. Today, I am totally convinced that we can deliver safe and effective  medicine for the treatment of chronic, neuropathic pain”.

Bengt von Mentzer, founder and chief scientific advisor

Latest news

View all
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Visionaries in pain relief: PharmNovo presents Bengt von Mentzer, founder and Chief scientific advisor.

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more
January 30, 2024

Meet Olof Breuer, MD, Clinical pharmacology lead

Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.

Read more